Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.
The use of induced pluripotent stem cells (iPSCs) as a cell source for producing cytotoxic T lymphocytes (CTLs) is expected to have advantages in the antigen specificity, rejuvenation profile, and reproducible number of CTLs. We have developed the way to differentiate CD8αβ T cells from TCR-transduced iPSCs (TCR-iPSCs). These T cells express monoclonal expression of the transduced TCR. Generating CD8αβ CTLs from TCR-iPSC could contribute to safe and effective allogeneic regenerative T cell immunotherapies.